• The FDA has provided information that strengthens the proposed clinical development plan for glenzocimab in acute ischemic stroke.
• A new type C consultation was granted by the FDA on the pharmaceutical development strategy
• In Europe, requests for additional scientific advice under the PRIME program have been validated by the EMA
• In the ACTISAVE study, 300 patients have already been recruited and 100 patients have been treated with thrombolysis and thrombectomy, thus reaching the target set for the first futility analysis
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]